SAN DIEGO, Jan. 31, 2012 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) ("REVA" or the "Company") is pleased to announce that representatives of the Company will present at two upcoming scientific conferences. Dr. Greg Kaluza, Director of Research for the Skirball Center for Cardiovascular Research in New York, will present at the LDDR 2012 Conference on February 3, 2012 at 1:45 p.m. CET. The conference is being held at the Mandarin Oriental Hotel in Geneva Switzerland. Dr. Alexandre Abizaid, principal investigator for REVA's RESTORE clinical trial, will present at the Cardiovascular Research Technologies ("CRT 2012") Conference on February 6, 2012 at 1:45 p.m. US EST. The conference is being held at the Omni Shoreham Hotel in Washington DC.
The information contained in these presentations has been previously disclosed. Copies of REVA's public presentations, which include recent disclosures, may be accessed under the Investor Relations section of the REVA website at www.revamedical.com.
About REVA
REVA is a development stage medical device company incorporated in Delaware, USA, that is focused on the development and eventual commercialisation of its proprietary, bioresorbable stent products. REVA's lead product, the ReZolve™ scaffold, combines REVA's proprietary stent design with a proprietary polymer that is metabolized and cleared from the body. The ReZolve scaffold is designed to offer full x-ray visibility, clinically relevant sizing and a controlled and safe resorption rate. In addition, by early encapsulation of the stent in the artery tissue coupled with the loss of scaffold structure over time, the ReZolve scaffold may reduce the incidence of late forming blood clots, or thrombosis, a rare but serious problem associated with drug-eluting metal stents currently on the market. REVA will require clinical results and regulatory approval before it can begin selling the ReZolve scaffold.
The REVA Medical, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8505